{"id":60882,"date":"2024-02-28T07:13:05","date_gmt":"2024-02-28T07:13:05","guid":{"rendered":"https:\/\/medsname.com\/dytor\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"dytor","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nb\/product\/dytor\/","title":{"rendered":"Dytor"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Dytor?<\/h3>\n<p style=\"margin:0;\"><strong>Dytor<\/strong> er en <strong>5 \/ 10 \/ 20 mg torasemide tablet<\/strong> from Cipla &mdash; a <strong>loop diuretic (pyridine-sulfonylurea structure)<\/strong> som virker p\u00e5 <strong>NKCC2 (Na-K-2Cl cotransporter) in the thick ascending limb<\/strong>. Torasemide (torsemide in US nomenclature) was introduced by Boehringer Mannheim in 1993 &mdash; the third major loop diuretic after furosemide and bumetanide. Marketed on its predictable bioavailability and longer duration vs furosemide. Half-life 3-4 hours (longer than furosemide); onset 30-60 minutes; peak effect 1-2 hours; duration 6-8 hours. Primary indication: <strong>chronic heart-failure oedema, hypertension (including refractory), hepatic ascites, oedema of chronic kidney disease<\/strong>. Typisk dosering: <strong>Hypertensjon:<\/strong> 5-10 mg once daily in the morning. Torasemide is the <strong>only loop diuretic with reasonable antihypertensive evidence<\/strong> &mdash; its longer effect duration and additional anti-aldosterone\/anti-fibrotic activity make it better suited for once-daily BP control than furosemide. Key contraindications: see full list below. Monitor electrolytes, creatinine, and glucose. <strong>Kombiner ikke med litium<\/strong> (tiazid-\/sl\u00f8yfediuretika kan utl\u00f8se litiumtoksisitet). <strong>Bruk under graviditet vurderes individuelt<\/strong> (se graviditetsmerknad). For de fleste hypertensjonspasienter fungerer diuretika best som <strong>andre eller tredje middel<\/strong> \u2014 vanligvis kombinert med en ARB, ACE-hemmer eller kalsiumkanalblokker snarere enn brukt alene.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Hva du f\u00e5r med MedsBase:<\/strong> WHO-GMP-sertifisert produsent \u00b7 Diskret emballasje \u00b7 Verdensomspennende levering \u00b7 1 400+ verifiserte <a href=\"https:\/\/medsbase.com\/nb\/reviews\/\">kundeanmeldelser<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Hver ordre er dekket av v\u00e5r <a href=\"https:\/\/medsbase.com\/nb\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis pakken din ikke ankommer innen 20 virkedager, sender vi ny.<\/p>\n<h3>Hvorfor bestille fra MedsBase<\/h3>\n<p>V\u00e5re generiske legemidler kommer fra WHO-GMP-sertifiserte produsenter og sendes over hele verden i diskret, n\u00f8ytral emballasje \u2014 ingen legemiddelnavn p\u00e5 utsiden av pakken. Kortbetalinger h\u00e5ndteres av en regulert betalingsbehandler (kontoutskrifter viser en regulert kortbetalingsprosessor \u2014 aldri \u201cMedsBase\u201d eller noe legemiddelnavn). Krypto og SEPA bankoverf\u00f8rsel godtas ogs\u00e5. Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy.<\/p>\n<h2 class=\"wp-block-heading\">What Is Dytor?<\/h2>\n<p>Dytor is an oral 5 \/ 10 \/ 20 mg torasemide tablet from Cipla, supplied in 30-180 tablets. Torasemide (torsemide in US nomenclature) was introduced by Boehringer Mannheim in 1993 &mdash; the third major loop diuretic after furosemide and bumetanide. Marketed on its predictable bioavailability and longer duration vs furosemide.<\/p>\n<h2 class=\"wp-block-heading\">How Torasemide Works<\/h2>\n<p>Torasemide inhibits the <strong>NKCC2 (Na-K-2Cl cotransporter) in the thick ascending limb<\/strong>. De nedstr\u00f8mmende effektene:<\/p>\n<ul>\n<li><strong>Dramatic reduction in sodium reabsorption<\/strong> &mdash; loop diuretics block the largest sodium-reabsorbing segment of the nephron; up to 25% of filtered sodium can be excreted<\/li>\n<li><strong>Large diuresis<\/strong> within 1-2 hours of oral dosing (5 minutes IV) &mdash; useful for acute decompensated heart failure and pulmonary oedema<\/li>\n<li><strong>Loss of magnesium and calcium<\/strong> in addition to sodium and potassium &mdash; contrasts with thiazides which retain calcium<\/li>\n<li><strong>Direct venodilation<\/strong> within minutes of IV dosing &mdash; contributes to symptom relief in acute pulmonary oedema before the diuresis arrives<\/li>\n<li><strong>Activates prostaglandin synthesis<\/strong> in the kidney &mdash; the basis of the NSAID interaction (NSAIDs blunt loop diuretic effect)<\/li>\n<li><strong>Mild mineralocorticoid receptor antagonism<\/strong> &mdash; reduces hypokalaemia and provides partial anti-fibrotic activity on myocardium<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Godkjente og evidensbaserte bruksomr\u00e5der<\/h2>\n<ul>\n<li><strong>Chronic heart-failure oedema, hypertension (including refractory), hepatic ascites, oedema of chronic kidney disease<\/strong> \u2014 prim\u00e6r indikasjon<\/li>\n<li><strong>Chronic heart failure with oedema<\/strong><\/li>\n<li><strong>Cirrhotic ascites<\/strong> (combined with spironolactone)<\/li>\n<li><strong>Hypertension, including refractory hypertension<\/strong> (only loop diuretic with reasonable HTN evidence)<\/li>\n<li><strong>CKD-related oedema<\/strong> &mdash; effective at eGFR &lt;30 where thiazides fail<\/li>\n<li><strong>Furosemide non-response<\/strong> &mdash; switching to torasemide often restores response due to better bioavailability<\/li>\n<\/ul>\n<p><strong>Avgj\u00f8rende studieresultater:<\/strong> <strong>TORIC trial (2002)<\/strong> &mdash; observational study of 1,377 HF patients; torasemide vs furosemide, torasemide arm showed 52% lower mortality. Widely cited but criticised for non-randomised design. <strong>TRANSFORM-HF (2023)<\/strong> &mdash; large randomised trial of 2,859 HF patients, torasemide vs furosemide; <strong>no significant difference<\/strong> in all-cause mortality at 12 months. Current verdict: torasemide is at least as good as furosemide; the choice turns on bioavailability, convenience, and tolerability rather than mortality.<\/p>\n<h2 class=\"wp-block-heading\">Dytor Dosage<\/h2>\n<p><strong>Chronic dose:<\/strong> <strong>Hypertensjon:<\/strong> 5-10 mg once daily in the morning. Torasemide is the <strong>only loop diuretic with reasonable antihypertensive evidence<\/strong> &mdash; its longer effect duration and additional anti-aldosterone\/anti-fibrotic activity make it better suited for once-daily BP control than furosemide.<\/p>\n<p><strong>Andre indikasjoner:<\/strong> <strong>Hjertesvikt:<\/strong> 10-20 mg PO daily initially; titrate to 10-100 mg\/day. Once-daily dosing is typically adequate. <strong>Cirrhotic ascites:<\/strong> 5-40 mg\/day in combination with spironolactone 100-200 mg\/day. <strong>CKD oedema:<\/strong> higher doses required (20-100 mg\/day) as nephrons drop.<\/p>\n<p><strong>Administrering:<\/strong> en gang daglig (eller to ganger daglig ved h\u00f8ye doser av sl\u00f8yfediumidika ved hjertesvikt), om morgenen. Kveldsdosering for\u00e5rsaker nokturi og b\u00f8r unng\u00e5s n\u00e5r mulig. Ta til samme tid hver dag. Mat p\u00e5virker ikke opptaket av disse diuretikaene signifikant.<\/p>\n<p><strong>Overv\u00e5kingsplan:<\/strong><\/p>\n<ul>\n<li><strong>Utgangspunkt:<\/strong> urinstoff, elektrolytter (spesielt kalium og natrium), kreatinin, eGFR, glukose, serumurat. Hjemme- eller klinikk-blodtrykk og daglig vekt for hjertesviktpasienter.<\/li>\n<li><strong>1-2 uker etter start eller doseendring:<\/strong> gjenta U&amp;E og kreatinin. Forvent milde elektrolyttendringer; unders\u00f8k betydelige endringer.<\/li>\n<li><strong>4-6 uker:<\/strong> Blodtrykkvurdering og fullt metabolsk panel.<\/li>\n<li><strong>L\u00f8pende:<\/strong> \u00e5rlig U&amp;E, urat, glukose og lipidpanel n\u00e5r stabilisert. Hyppigere ved CKD, HF eller ved kombinasjonsterapi.<\/li>\n<li><strong>Stopp eller reduser dose ved:<\/strong> natrium &lt;130 med symptomer, kalium 5,5, kreatinin\u00f8kning &gt;30%, ny gikt, alvorlige dehydreringssymptomer.<\/li>\n<\/ul>\n<p><strong>Avslutning:<\/strong> ingen abstinenssyndrom, men plutselig stopp kan for\u00e5rsake rebound v\u00e6skeretensjon hos HF-pasienter p\u00e5 kronisk h\u00f8ydose sl\u00f8yfediuretika \u2014 trapp ned der mulig og overv\u00e5k vekt.<\/p>\n<ul>\n<li><strong>Bioavailability 80-100%<\/strong> (furosemide 10-90%) &mdash; particularly useful in patients with congested heart failure, gut oedema, or inconsistent response to furosemide.<\/li>\n<li><strong>Mild aldosterone antagonism<\/strong> &mdash; partial anti-fibrotic activity in myocardium. Clinical significance modest; probably contributes to why TORIC showed benefit.<\/li>\n<li><strong>Less hypokalaemic<\/strong> than furosemide at equivalent natriuretic doses (related to the aldosterone-antagonist effect).<\/li>\n<li><strong>Equivalence dosing:<\/strong> torasemide 10 mg &asymp; furosemide 40 mg. Useful when switching patients between agents.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Bivirkninger<\/h2>\n<p><strong>Vanlige (&gt;1%):<\/strong><\/p>\n<ul>\n<li><strong>Hypokalemi<\/strong> (less than furosemide)<\/li>\n<li><strong>Hypomagnesemi<\/strong><\/li>\n<li><strong>Hyponatremi<\/strong><\/li>\n<li><strong>Pre-renal AKI<\/strong> in over-diuresis<\/li>\n<li><strong>Ototoxicity<\/strong> (rare; less than furosemide per unit of natriuresis)<\/li>\n<li><strong>Hyperurikemi<\/strong><\/li>\n<li><strong>Mild hyperglykemi<\/strong><\/li>\n<li><strong>Postural hypotensjon<\/strong><\/li>\n<li><strong>Svimmelhet, hodepine<\/strong><\/li>\n<\/ul>\n<p><strong>Uvanlig, men klinisk viktig:<\/strong><\/p>\n<ul>\n<li><strong>Alvorlig hyponatremi<\/strong> \u2014 spesielt hos eldre med lavtsaltdieter, SIADH-tilstander, eller kombinert med SSRI. Kan manifestere seg som forvirring, fall eller kramper.<\/li>\n<li><strong>Pankreatitt<\/strong> \u2014 sjelden tiazid-\/sl\u00f8yfeklasseeffekt; stopp umiddelbart ved \u00f8vre magesmerter med lipasestigning<\/li>\n<li><strong>Trombocytopeni, leukopeni, agranulocytose<\/strong> \u2014 sjeldne hypersensitivitetsreaksjoner (vanligere med tiazider enn sl\u00f8yfedrivende midler)<\/li>\n<li><strong>Akutt myopi og vinkelblokkglaukom<\/strong> \u2014 sjelden sulfonamidklassereaksjon innen timer til dager etter start; stopp umiddelbart ved plutselig smertefullt \u00f8ye eller synsendring<\/li>\n<li><strong>Stevens-Johnson-syndrom \/ toksisk epidermal nekrolyse<\/strong> \u2014 ekstremt sjelden, men rapportert<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Kontraindikasjoner<\/h2>\n<ul>\n<li>Anuri<\/li>\n<li>Overf\u00f8lsomhet for sulfonamider<\/li>\n<li>Severe hepatic failure with hepatic coma<\/li>\n<li>Severe hyponatraemia or hypokalaemia at baseline<\/li>\n<li>Severe dehydration and pre-renal azotaemia<\/li>\n<\/ul>\n<p><strong>Graviditet:<\/strong> avoided for routine hypertension; use only for clear indications (pulmonary oedema, resistant HF) under specialist care. Loop diuretics cross the placenta and can reduce fetal urine output.<\/p>\n<p><strong>Amming:<\/strong> vanligvis akseptabelt i lave doser; h\u00f8ye doser kan redusere melkeproduksjonen (spesielt tiazider). Alternative antihypertensiva (propranolol, nifedipin) foretrekkes n\u00e5r mulig.<\/p>\n<h2 class=\"wp-block-heading\">Legemiddelinteraksjoner<\/h2>\n<ul>\n<li><strong>Litium \u2014 KRITISK INTERAKSJON.<\/strong> Tiazid- og sl\u00f8yfediuretika reduserer litiums renale klaring og kan utl\u00f8se litiumtoksisitet. Unng\u00e5 kombinasjon hvis mulig; hvis det er uunng\u00e5elig, overv\u00e5k litiumniv\u00e5er ukentlig den f\u00f8rste m\u00e5neden og reduser litiumdosen med 25-50%.<\/li>\n<li><strong>NSAID-er<\/strong> \u2014 reduserer diuretisk effekt (via prostaglandinblokkade) og \u00f8ker betydelig risiko for akutt nyreskade (AKI) n\u00e5r kombinert med ACE-hemmere\/ARB (den \u201ctriple whammy\u201d). Bruk paracetamol som f\u00f8rstevalg ved kroniske smerter.<\/li>\n<li><strong>ACE-hemmere og ARB<\/strong> \u2014 kombinasjonen er standard og gunstig ved h\u00f8yt blodtrykk; tillegg av ACE-hemmer\/ARB blokkerer kompensatorisk RAAS-aktivering og forsterker den diuretiske effekten. Overv\u00e5k kalium og kreatinin.<\/li>\n<li><strong>Kaliumtilskudd og kaliumsparende diuretika<\/strong> \u2014 ofte n\u00f8dvendig for \u00e5 motvirke hypokalemi for\u00e5rsaket av loop-\/tyaziddiuretika. Overv\u00e5k kalium; unng\u00e5 overkorrigering.<\/li>\n<li><strong>Digoxin<\/strong> \u2014 hypokalemi forsterker digoksintoksisteten (loop- og tyaziddiuretika); spironolakton reduserer direkte digoksinklaringen. Overv\u00e5k digoksinniv\u00e5er og kalium ved start eller endring av diuretika.<\/li>\n<li><strong>Orale kortikosteroider, amfotericin B, stimulerende avf\u00f8ringsmidler<\/strong> \u2014 additiv hypokalemi (loop\/tyazid) eller maskert kaliumbehov (spironolakton).<\/li>\n<li><strong>Orale antidiabetika, insulin<\/strong> \u2014 tyazider og (i mindre grad) loop-diuretika forverrer glukosetoleransen; kan kreve dosejustering.<\/li>\n<li><strong>Kolestyramin \/ kolestipol<\/strong> \u2014 reduserer opptaket av tyazider og loop-diuretika med 40-85%. Separer dosering med 4 timer.<\/li>\n<li><strong>Aminoglycoside antibiotics (gentamicin, amikacin)<\/strong> &mdash; additive ototoxicity. Avoid concurrent use at high IV doses.<\/li>\n<li><strong>Alkohol<\/strong> \u2014 additiv postural hypotensjon.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Where Dytor Fits in the Diuretic Class<\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:14px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Klasse<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Representanter<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Typisk bruk<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Thiazid<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><a href=\"https:\/\/medsbase.com\/nb\/aquazide\/\">HCTZ<\/a>, chlortalidon<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">F\u00f8rstelinje ved HTN, nyrestein, nefrogen DI<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Thiazid-lignende<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><a href=\"https:\/\/medsbase.com\/nb\/natrilix-sr\/\">Indapamid<\/a>, metolazon<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">HTN (eldre, HYVET-dokumentert), sekvensiell nefronblokkering<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Loop (kortvarig)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><a href=\"https:\/\/medsbase.com\/nb\/lasix\/\">Furosemid<\/a>, bumetanid<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Akutt lunge\u00f8dem, CHF, ascites, hyperkalc\u00e6mi<\/td>\n<\/tr>\n<tr style=\"background:#fff3cd;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Loop (langvarig)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><a href=\"https:\/\/medsbase.com\/nb\/dytor\/\">Torasemid<\/a><\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Kronisk CHF, HTN (eneste loop med dokumentert effekt ved HTN), \u00f8dem ved CKD<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Aldosteronantagonist<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><a href=\"https:\/\/medsbase.com\/nb\/aldactone\/\">Spironolacton<\/a>, eplerenone<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">HF-REF (RALES), resistent HTN (PATHWAY-2), Conn\u2019s, cirrotisk ascites<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Andre K-sparende<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Amilorid, triamteren (vanligvis i kombinasjoner)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Forebygging av hypokalemi n\u00e5r det tilsettes loop\/thiazid<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Karbonsyreanhydrase<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Acetazolamid<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">H\u00f8ydekreft, glaukom, metabolsk alkalose<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Oppbevaring<\/h2>\n<p>Store Dytor below 25&deg;C in the original blister pack. Keep out of reach of children.<\/p>\n<h2 id=\"faqs\">Vanlige sp\u00f8rsm\u00e5l<\/h2>\n<h3 class=\"wp-block-heading\">When should I take Dytor &mdash; morning or evening?<\/h3>\n<p><strong>Morgen<\/strong> in almost all cases. The diuretic effect produces increased urine output for 2-4 hours after dosing. Evening dosing causes nocturia and disrupts sleep. Patients on twice-daily loop diuretics typically dose at breakfast and early afternoon (not bedtime).<\/p>\n<h3 class=\"wp-block-heading\">Is Dytor a first-line blood-pressure drug?<\/h3>\n<p><strong>Nei.<\/strong> Loop diuretics are <strong>not first-line antihypertensives<\/strong> &mdash; they are too short-acting and produce BP swings. Loop diuretics are used for hypertension only in specific situations: concurrent heart-failure oedema, advanced CKD (eGFR &lt;30) where thiazides fail, or resistant hypertension as an add-on. For standard hypertension, choose a thiazide, ARB, ACE inhibitor, or calcium-channel blocker instead.<\/p>\n<h3 class=\"wp-block-heading\">Will Dytor affect my potassium?<\/h3>\n<p>Yes &mdash; Dytor <strong>senker<\/strong> kalium ved \u00e5 \u00f8ke kaliumutsondringen i distale tubuli. Overv\u00e5k ved start, etter 1-2 uker og periodisk. Hypokalemirisiko <strong>minimeres ved \u00e5 kombinere<\/strong> Dytor with an ARB or ACE inhibitor &mdash; which is the standard combination in hypertension anyway. If potassium drops below 3.5 in isolated diuretic use, add potassium supplementation, a potassium-rich diet, or a small dose of a potassium-sparing agent (spironolactone, eplerenone, or an <a href=\"https:\/\/medsbase.com\/nb\/amifru\/\">amiloridholdig kombinasjon<\/a>).<\/p>\n<h3 class=\"wp-block-heading\">I have gout &mdash; can I take Dytor?<\/h3>\n<p>Med forsiktighet. Tiazider og (i mindre grad) sl\u00f8yfediuretika \u00f8ker serumurinsyre ved \u00e5 konkurrere om ekskresjon i proximale tubuli. Hos giktutl\u00f8ste pasienter: foretrekk losartanbaserte kombinasjoner (<a href=\"https:\/\/medsbase.com\/nb\/cosart-h\/\">Cosart H<\/a>, <a href=\"https:\/\/medsbase.com\/nb\/cozartan-h\/\">Cozartan H<\/a>) whose losartan component is uniquely uricosuric and offsets the thiazide urate rise. If Dytor is already in use and gout flares, add or continue urate-lowering therapy (allopurinol) rather than stopping Dytor outright.<\/p>\n<h3 class=\"wp-block-heading\">I&rsquo;m diabetic &mdash; is Dytor safe?<\/h3>\n<p>Mostly yes, but be aware that thiazides and (to a lesser extent) loop diuretics <strong>modestly worsen glucose tolerance<\/strong> (average fasting glucose rise 5-8 mg\/dL, HbA1c 0.1-0.3%). The BP benefit outweighs this in most diabetics. If you want a more metabolically neutral combination, ARB+CCB is an alternative (<a href=\"https:\/\/medsbase.com\/nb\/olmezest-am\/\">Olmezest AM<\/a>).<\/p>\n<h3 class=\"wp-block-heading\">Can I take ibuprofen with Dytor?<\/h3>\n<p>Kortvarig bruk av og til er vanligvis greit. Langvarig daglig bruk av NSAID-er (ibuprofen, diklofenak, naproxen) <strong>reduserer diuretisk og antihypertensiv effekt<\/strong> of Dytor (prostaglandin blockade) and substantially raise the AKI risk when combined with an ACE inhibitor or ARB &mdash; the &#8220;triple whammy.&#8221; Use paracetamol preferentially for chronic pain.<\/p>\n<h3 class=\"wp-block-heading\">M\u00e5 jeg tisse mer om natten?<\/h3>\n<p>Usually no, if you take Dytor in the morning. The diuretic effect peaks 2-4 hours after dosing and has mostly worn off by evening. Nocturia is a common complaint when patients switch to evening dosing; switch back to morning dosing and nocturia resolves within 1-3 days.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Dytor in pregnancy?<\/h3>\n<p>Routinely avoided. Loop diuretics cross the placenta and can affect the fetus. For hypertension in pregnancy, switch to <a href=\"https:\/\/medsbase.com\/nb\/labebet\/\">labetalol<\/a>, metyldopa eller nifedipin. Diuretika brukes under svangerskap kun for spesifikke indikasjoner (lunge\u00f8dem, resistent hjertesvikt) under spesialistveiledning.<\/p>\n<h3 class=\"wp-block-heading\">Hva om jeg glemmer en dose?<\/h3>\n<p>Ta den s\u00e5 snart du husker det, med mindre det er nesten tid for neste dose \u2014 i s\u00e5 fall hopp over den glemte dosen. Ikke ta dobbel dose. En enkelt glemt dose p\u00e5virker ikke langtidskontrollen av blodtrykk eller v\u00e6ske balanse betydelig.<\/p>\n<h3 class=\"wp-block-heading\">Where can I buy Dytor online?<\/h3>\n<p>You can buy Dytor (5 \/ 10 \/ 20 mg torasemide, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.<\/p>\n<h2 class=\"wp-block-heading\">Relaterte antihypertensiva og diuretika p\u00e5 MedsBase<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/nb\/amifru\/\">Amifru \u2014 Furosemid + Amilorid (sl\u00f8yfe- + K-sparende)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/cosart-h\/\">Cosart H &mdash; Losartan + HCTZ fixed combination<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/losar\/\">Losar \u2014 Losartan (ARB-partner for diuretikum)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/natrilix-sr\/\">Natrilix SR \u2014 Indapamid 1,5 mg SR (tiazid-lignende)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/ramcor\/\">Ramcor &mdash; Ramipril (ACEi partner for diuretic)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/telmaheal\/\">Telmaheal &mdash; Telmisartan (ARB partner for diuretic)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/high-blood-pressure-medication\/\"><strong>Se alle h\u00f8yt blodtrykksmedikamenter<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 Medisinsk ansvarsfraskrivelse.<\/strong> Denne siden er kun til informasjonsform\u00e5l og erstatter ikke medisinsk r\u00e5dgivning fra en kvalifisert helsepersonell. H\u00f8yt blodtrykk, hjertesvikt og arytmier krever diagnose, overv\u00e5kning og dosindividualisering av en lege \u2013 bruk alltid betablokkere under medisinsk veiledning.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Relaterte alternativer<\/h3>\n<p>Andre produkter innen <strong>Kroniske tilstander<\/strong> som kunder ogs\u00e5 ser p\u00e5:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/nb\/voritrol\/\">Voritrol<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/glynase-mf\/\">Glynase-MF<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/arkamin-h\/\">Arkamin-H<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/fluvoxin\/\">Fluvoxin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/hydrosar\/\">Hydrosar<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Dytor is Cipla&#8217;s torasemide 5\/10\/20 mg tablets \u2014 long-acting loop diuretic with 80-100% predictable bioavailability (vs furosemide 10-90%). Preferred in patients with gut oedema, inconsistent furosemide response, or needing once-daily loop coverage. Mild aldosterone antagonism reduces hypokalaemia. Only loop diuretic with reasonable hypertension evidence. TRANSFORM-HF 2023 \u2014 equivalent mortality to furosemide in heart failure.<\/p>","protected":false},"featured_media":0,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3260,3356],"product_tag":[4941,4942],"class_list":{"0":"post-60882","1":"product","2":"type-product","3":"status-publish","5":"product_cat-category-overview","6":"product_cat-chronic-conditions","7":"product_cat-heart-blood-pressure","8":"product_cat-high-blood-pressure-medication","9":"product_tag-dytor","10":"product_tag-torasemide","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product\/60882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/comments?post=60882"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/media?parent=60882"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_brand?post=60882"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_cat?post=60882"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_tag?post=60882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}